Skip to main content
CSL
  • Global Selector
  • Newsroom
  • Partnering
  • Contact
  • We Are CSL
    We Are CSL
    Our Businesses and Products
    Vita: Original Stories
    Our Leadership
    Worldwide Locations
    Corporate Governance
    Our Businesses and Products
    CSL Behring
    CSL Seqirus
    CSL Vifor
    Corporate Governance
    Code of Responsible Business Practice
    Core Policies

    Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.

    Read the Stories

    CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.

    Our Businesses and Products
  • Patients & Public Health
    Patients & Public Health
    Rare & Serious Diseases
    Iron Deficiency
    Nephrology
    Vaccines
    Patient Support & Organizations
    Rare & Serious Diseases
    Immunodeficiency and Autoimmune Diseases
    Hereditary Bleeding Disorders
    Hereditary Angioedema
    Alpha 1 Antitrypsin Deficiency
    Iron Deficiency
    Iron Deficiency Patient Stories
    Nephrology
    Nephrology Patient Stories
    Vaccines
    COVID-19
    Pandemic Response
    In-Licensing
    Antivenoms and Q fever Vaccine
    Patient Support & Organizations
    CSL Behring USA Support & Assistance Programs
    CSL Vifor Managed Access Programs
    LEAD Grants
    CSL Community Impact Awards

    Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.

    CSL Behring: Rare & Serious Diseases

    Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.

    CSL Seqirus: Vaccines
  • R&D
    R&D
    R&D Capabilities
    Awards, Grants and Initiatives
    World-Class R&D Network
    Product Pipeline
    Clinical Studies at CSL
    Clinical Studies at CSL
    Current Clinical Trials
    Research Practices
    How to Participate
    Clinical Studies FAQs

    R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.

    R&D Capabilities

    One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.

    Awards, Grants and Initiatives
  • Sustainability
    Sustainability
    Healthier Environment
    Healthier Communities
    Promising Futures
    Governance
    Data and Reporting Centre
    Healthier Environment
    Climate Resilience
    Energy
    Water and Waste
    Healthier Communities
    Product Safety & Quality
    Innovation and R&D
    Access and Affordability
    Responsible & Resilient Supply Chain
    Donor Experience
    Patient Experience
    Promising Futures
    Talent and Culture
    Health, Safety & Wellbeing
    Inclusion and Belonging
    Governance
    Ethics & Transparency
    Data Protection & Privacy
    Stakeholder Engagement & Material Topics
    Data and Reporting Centre
    Annual Publications
    Policies
    Key Performance Data Summary

    As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.

    Learn About Our Targets

    Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.

    Supporting Our Communities
  • Careers
    Careers
    Inclusion and Belonging
    How CSL Supports Your Well-being
    Early Careers at CSL
    Early Careers at CSL
    Apprenticeships
    Internships at CSL
    Graduate Rotational Programs at CSL

    At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.

    Read About Our Approach to Inclusion and Belonging

    Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!

    Early Careers at CSL
  • Investors
CSL

  • We Are CSL
    • We Are CSL
    • Our Businesses and Products
      • Our Businesses and Products
      • CSL Behring
      • CSL Seqirus
      • CSL Vifor
    • Vita: Original Stories
    • Our Leadership
    • Worldwide Locations
    • Corporate Governance
      • Corporate Governance
      • Code of Responsible Business Practice
      • Core Policies
  • Patients & Public Health
    • Patients & Public Health
    • Rare & Serious Diseases
      • Rare & Serious Diseases
      • Immunodeficiency and Autoimmune Diseases
      • Hereditary Bleeding Disorders
      • Hereditary Angioedema
      • Alpha 1 Antitrypsin Deficiency
    • Iron Deficiency
      • Iron Deficiency
      • Iron Deficiency Patient Stories
    • Nephrology
      • Nephrology
      • Nephrology Patient Stories
    • Vaccines
      • Vaccines
      • COVID-19
      • Pandemic Response
      • In-Licensing
      • Antivenoms and Q fever Vaccine
    • Patient Support & Organizations
      • Patient Support & Organizations
      • CSL Behring USA Support & Assistance Programs
      • CSL Vifor Managed Access Programs
      • LEAD Grants
      • CSL Community Impact Awards
  • R&D
    • R&D
    • R&D Capabilities
    • Awards, Grants and Initiatives
    • World-Class R&D Network
    • Product Pipeline
    • Clinical Studies at CSL
      • Clinical Studies at CSL
      • Current Clinical Trials
      • Research Practices
      • How to Participate
      • Clinical Studies FAQs
  • Sustainability
    • Sustainability
    • Healthier Environment
      • Healthier Environment
      • Climate Resilience
      • Energy
      • Water and Waste
    • Healthier Communities
      • Healthier Communities
      • Product Safety & Quality
      • Innovation and R&D
      • Access and Affordability
      • Responsible & Resilient Supply Chain
      • Donor Experience
      • Patient Experience
    • Promising Futures
      • Promising Futures
      • Talent and Culture
      • Health, Safety & Wellbeing
      • Inclusion and Belonging
    • Governance
      • Governance
      • Ethics & Transparency
      • Data Protection & Privacy
      • Stakeholder Engagement & Material Topics
    • Data and Reporting Centre
      • Data and Reporting Centre
      • Annual Publications
      • Policies
      • Key Performance Data Summary
  • Careers
    • Careers
    • Inclusion and Belonging
    • How CSL Supports Your Well-being
    • Early Careers at CSL
      • Early Careers at CSL
      • Apprenticeships
      • Internships at CSL
      • Graduate Rotational Programs at CSL
  • Investors
  • Newsroom
  • Partnering
  • Contact
  • Global Selector

Did you know? CSL is investigating a potential treatment to improve the health of people living with end-stage kidney disease (ESKD). 

ESKD patients face an increased risk of cardiac events, like heart attacks and strokes.

Learn More From Patients

CSL's 2025 Half Year Financial Results Click here for Full Information including Webcast Recording →   |    Would you like to read our 2024 Annual Report? Click here to view or download the Annual Report →

CSL
CSL Behring
CSL Seqirus
CSL Vifor

CSL. Always Evolving for a Better World.

CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.

Our Businesses and Products

CSL Behring. Leading the Way in Treating Rare and Serious Diseases.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.

More About CSL Behring

CSL Seqirus. Global Vaccine Leader.

Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.

More About CSL Seqirus

CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.

The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

More About CSL Vifor
CSL Logo The text 'CSL' in bold white all capitals.
CSL Behring Logo The text 'CSL Behring' in bold white.
CSL Seqirus Logo The text 'CSL Seqirus' in bold white.
CSL Vifor Logo The text 'CSL Vifor' in bold white.
CSL Logo

CSL. Always Evolving for a Better World.

CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.

Our Businesses and Products
CSL Behring Logo

CSL Behring. Leading the Way in Treating Rare and Serious Diseases.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.

More About CSL Behring
CSL Seqirus Logo

CSL Seqirus. Global Vaccine Leader.

Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.

More About CSL Seqirus
CSL Vifor Logo

CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.

The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

More About CSL Vifor

Vita: Original Stories

'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.

Two skateboarders walk down a path in autumn

A New Era of Hemophilia Care

We share a recent sponsored article in Politico and reports from Danish news outlets.

27 May 2025
Participants in the CSL-sponsored Hackathon at Drexel University

CSL Supported Hackathons at Three Universities

CSL sponsored recent hackathon events that attracted students to find creative solutions to business problems.

22 May 2025
Vickie, a participant in a clinical trial for end-stage kidney disease (ESKD)

Video: Kidney Disease Patients in a Clinical Trial

Did you know? CSL is investigating a potential treatment to improve the health of people living with end-stage kidney disease…

19 May 2025
CSL scientist in Switzerland

Careers at CSL

We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?

Pictured: CSL employees in Melbourne, Australia

Promising Futures at CSL

CSL on LinkedIn

Follow us!
LinkedIn
2 Jun

Happy Pride Month! 🌈 Today and every day, we celebrate love, identity, and the power of living authentically. Here's to a world where everyone can shine as their true selves. https://bit.ly/43rcIPr #CSL #Pride #LoveIsLove

LinkedIn
1 Jun

Apply now for CSL's Award Winning Australian 2025 Intern Program! Join our collaborative, dynamic environment that fosters innovation. https://bit.ly/4dHHnLL #PromisingFutures #Internship #CSL #DoWorkThatMatters

LinkedInPostImage
LinkedIn
29 May

We thank Lily, a gold-medal-winning Special Olympics Pennsylvania athlete, for bringing so much sunshine to our King of Prussia, PA, campus on a rainy afternoon. An overflow crowd of employees turned out for CSL’s Special Olympics fundraiser, and "Lily from Philly", who also works at Lincoln Financial Field on game days, shared the story of her swimming victory at the USA Games. Learn more about the Special Olympics Pennsylvania , how the organization is making a difference for people with intellectual disabilities, and how you can help: https://bit.ly/4kJhrBO #SpecialOlympics #CSL #SpecialOlympicsPA

LinkedInPostImage
LinkedIn
29 May

1 in 50,000 people live with hereditary angioedema \(#HAE \) – a rare and debilitating genetic disease that causes painful and potentially life-threatening swelling attacks. Arianna is just one of those affected by HAE, and it’s for people like her that we strive to ‘never give up’ to tirelessly advance new solutions for HAE treatments and provide hope to all those affected by HAE. Read more of Arianna’s experience with HAE and her hopes for the future of HAE treatment: https://lnkd.in/eT9XUEjU #CSL

LinkedIn
28 May

Plasma Partners! We were delighted to host Australian Red Cross Lifeblood for a behind-the-scenes tour of our CSL Plasma Operations in the US. With stops at our Knoxville Testing Laboratory and our Greenacres Collection Centre, we discussed all things plasma collection, medical operations and donor experience. Learn more about CSL and what we do here: https://bit.ly/43jUTlk #CSL #CSLPlasma #AustralianRedCrossLifeblood

LinkedIn
28 May

For over a century, CSL has been dedicated to advancing biotechnology and developing life-changing therapies for those with rare and serious diseases. Our commitment to innovation has positioned us as a leader with a clear mission: to save and improve lives through groundbreaking science. By staying at the forefront of medical advancements, we continue to transform patient outcomes and set new standards in health care. #InnovationForLife #AdvancingHealthCare Learn more about our history and impact: https://bit.ly/4kfuDyx

LinkedInPostImage
LinkedIn
26 May

Applications for the 2026 CSL Centenary Fellowships are now open and will be accepted until 30 June 2025. Dr Clare Weeden from WEHI (Walter and Eliza Hall Institute of Medical Research) is one of our 2025 CSL Centenary Fellows. She has shown that our lungs contain many thousands of potentially cancerous cells that can become cancer through inflammation caused by smoking and air pollution over the years. Clare is investigating these epigenetic changes to find out if she can reverse them. Australia’s top early-mid career biomedical researchers are invited to apply for one of two fellowships worth A$1.25 million over five years in support of discovery and translational medical research. The CSL Centenary Fellowships are an integral part of how CSL delivers on our promise to help foster a thriving medical research community by supporting the advancement of Australian science. For application details, visit: https://bit.ly/3SRD3Qn #CSL

LinkedIn
22 May

Meet Reagan Bender, who has thrived at CSL for 11 years! Starting in sales, Reagan's career has evolved through various roles, showcasing CSL's supportive and collaborative environment. By leveraging mentorship and thinking ahead, Reagan has grown within the organization and made a meaningful impact on patient lives. Discover how CSL can be the perfect place for your professional growth. https://bit.ly/4dDdts8 #CSLCareers #CareerGrowth #Mentorship #GreatPlaceToWork #JoinCSL #PromisingFutures

LinkedIn
22 May

Some symptoms you can see. Others stay hidden—and hit harder. Life doesn’t stop when you're diagnosed with ANCA-Associated Vasculitis \(AAV\). But everything quietly shifts. The disease rarely shows on the outside, yet it reaches into every corner of a person’s life. Yes, the body is affected—joint pain, fatigue, or physical changes that may be visible. But what truly defines the experience of living with AAV often lies beneath the surface. A promising career might be paused indefinitely. The plans, routines, and relationships that once felt solid begin to feel fragile. Even simple joys become difficult to hold onto when your body is in constant survival mode. The emotional weight is real—and often underestimated. There’s the fear of losing independence, the pressure of financial instability, the strain it can place on the people you love most, on a relationship with a partner. AAV affect how people see themselves, how they relate to others, how they envision their future. AAV doesn’t just attack the body—it attacks one’s sense of identity, stability, and purpose. That’s the side of AAV we don’t talk about enough. And that’s the side we’re here to acknowledge today. At CSL, we believe raising awareness means seeing the full picture. Not just the medical symptoms, but the human experience behind them. Because living with AAV is more than managing inflammation—it's managing life. Join us in supporting all those whose battles may be invisible, but never insignificant. Learn more on https://bit.ly/43s07Ki #AAVAwareness #LifeWithAAV

LinkedInPostImage
LinkedIn
21 May

At CSL, sustainability isn’t just a buzzword. It’s embedded in everything we do across the globe. We’re committed to reducing emissions, rethinking resources and designing facilities that support a healthier, more sustainable future. #PromisingFutures #CSL Reinvent the world with us: https://bit.ly/4kxW7z9

LinkedInPostImage

We Are CSL

  • Our Businesses and Products
  • Vita: Original Stories
  • Our Leadership
  • Worldwide Locations
  • Corporate Governance

Patients & Public Health

  • Rare & Serious Diseases
  • Iron Deficiency
  • Nephrology
  • Vaccines
  • Patient Support & Organizations

R&D

  • R&D Capabilities
  • Awards, Grants and Initiatives
  • World-Class R&D Network
  • Product Pipeline
  • Clinical Studies at CSL

Sustainability

  • Healthier Environment
  • Healthier Communities
  • Promising Futures
  • Governance
  • Data and Reporting Centre

Careers

  • Inclusion and Belonging
  • How CSL Supports Your Well-being
  • Early Careers at CSL

Investors

Terms of Use Cookie Policy Global Privacy Policy Accessibility Statement Sitemap
  • Terms of Use
  • Cookie Policy
  • Global Privacy Policy
  • Accessibility Statement
  • Sitemap
CSL logo

CSL, All Rights Reserved © 2025

  • Instagram

CSL
  • CSL (CSL Behring's Parent Company)
CSL Behring Worldwide

Americas

  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Mexico

Asia Pacific

  • Australia
  • China
  • Japan
  • Korea
  • Singapore
  • Taiwan

Middle East

  • Saudi Arabia
  • United Arab Emirates (MEA)

Europe

  • Austria
  • Belgium and Luxembourg
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
CSL Plasma (CSL Behring Subsidiary)
  • CSL Plasma US
  • CSL Plasma Germany
  • CSL Plasma Hungary